Skip to content

UPDATE: We are delighted to announce that EPSRC have funded our CDT for five more years under the new name EPSRC Centre for Doctoral Training in Intelligent Integrated Imaging in Healthcare (i4health).

Visit our new website at: www.ucl.ac.uk/i4health

Prof Matthias Koepp

UCL Institute of Neurology

Epilepsy Imaging Group, Department of Clinical and Experimental Epilepsy

Institute of Neurology

London

WC1N 3BG

m.koepp@ucl.ac.uk

Tel: 01494 601300

Fax: 01494 875666

https://www.ucl.ac.uk/ion/departments/epilepsy

Biography

My major research achievements have been:

  1. Development of an in-vivo imaging technique to demonstrate neurotransmitter fluxes induced by epileptic activity or through behavioural challenges. This widely cited and replicated work was the basis for a large programme of activities by the Psychiatry, Movement Disorder and Epilepsy Group at the MRC-CU. The main epilepsy-related finding from a series of experiments funded by this grant is the first direct human in vivo evidence for changes in opioid receptor availability over a time course of hours following spontaneous seizures, emphasizing further an important role of the opioid system in terminating seizure activity. Recently, we were able to show endogenous opioid release during a shift in mood in orbitogrontal and temporo-limbic areas known to be involved in processing positive memories.
  2. Conducted at the MRC Cyclotron Unit as an external program with funding from the MRC, Deutsche Forschungsgemeinschaft, I closely supervised investigations of the central benzodiazepine receptor complex in refractory epilepsy. The clinically most relevant publication evaluating the role of 11C-flumazenil PET for refractory focal epilepsies with normal MRI was awarded the prestigious biennial Michael Prize in 2001 by the International League against Epilepsy. Recently, I instigated investigations using a novel uncompetitive NMDA antagonist, 11C-CNS5161.

IRIS profile